{"pmid":32379913,"title":"Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.","text":["Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.","Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.","J Eur Acad Dermatol Venereol","Conti, A","Lasagni, C","Bigi, L","Pellacani, G","32379913"],"abstract":["Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Conti, A","Lasagni, C","Bigi, L","Pellacani, G"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379913","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16587","keywords":["sars-cov-2","covid-19","psoriasis; biologic","therapies"],"topics":["Case Report"],"weight":1,"_version_":1666597097303965696,"score":9.490897,"similar":[{"pmid":32358791,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor.","J Eur Acad Dermatol Venereol","Balestri, R","Rech, G","Girardelli, C R","32358791"],"abstract":["we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Rech, G","Girardelli, C R"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358791","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16571","keywords":["il17-inhibitor","sars-cov-2; covid-19; psoriasis","ixekizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495318491137,"score":254.83173},{"pmid":32478971,"title":"Psoriatic Arthritis and COVID-19 Pandemic: Consequences in Medical Treatment?","text":["Psoriatic Arthritis and COVID-19 Pandemic: Consequences in Medical Treatment?","The COVID-19 pandemic has a strong negative impact on human society world-wide. Patients with immune-mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID-19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID-19? Does systemic medical treatment pose an increased risk of infection with SARS-CoV-2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis - a factor with strong negative impact on COVID-19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID-19 pandemic and should be interpreted with caution. Some biologics demonstrated an anti-fibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In non-symptomatic PsA patients, systemic drug therapy can be continued. This article is protected by copyright. All rights reserved.","Dermatol Ther","Wollina, Uwe","Fioranelli, Massimo","Goldust, Mohamad","Lotti, Torello","32478971"],"abstract":["The COVID-19 pandemic has a strong negative impact on human society world-wide. Patients with immune-mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID-19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID-19? Does systemic medical treatment pose an increased risk of infection with SARS-CoV-2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis - a factor with strong negative impact on COVID-19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID-19 pandemic and should be interpreted with caution. Some biologics demonstrated an anti-fibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In non-symptomatic PsA patients, systemic drug therapy can be continued. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Wollina, Uwe","Fioranelli, Massimo","Goldust, Mohamad","Lotti, Torello"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478971","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dth.13743","keywords":["covid-19","psoriatic arthritis; systemic medical treatment","biologics","small molecules"],"topics":["Treatment"],"weight":1,"_version_":1668437834968596480,"score":205.65625},{"pmid":32356577,"title":"Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","text":["Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved.","Dermatol Ther","Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio","32356577"],"abstract":["During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356577","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13475","keywords":["bilateral interstitial pneumonia","biologics","covid-19","pandemic","psoriasis","psoriatic arthritis","sars-cov-2"],"locations":["Lombardia","Italian","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138495229362176,"score":191.23825},{"pmid":32379925,"title":"Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.","text":["Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.","We read with great interest the publication of Messina et al (1) reporting the first case of SARS-CoV2 infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23(2) .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the << cytokine storm >> triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms (3) .","J Eur Acad Dermatol Venereol","Benhadou, F","Del Marmol, V","32379925"],"abstract":["We read with great interest the publication of Messina et al (1) reporting the first case of SARS-CoV2 infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23(2) .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the << cytokine storm >> triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms (3) ."],"journal":"J Eur Acad Dermatol Venereol","authors":["Benhadou, F","Del Marmol, V"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379925","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16590","keywords":["covid-19","sars-cov2","biotherapy","guselkumab","psoriasis"],"e_drugs":["guselkumab"],"topics":["Case Report"],"weight":1,"_version_":1666262687702581248,"score":181.5076},{"pmid":32294258,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns.","J Eur Acad Dermatol Venereol","Messina, F","Piaserico, S","32294258"],"abstract":["Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns."],"journal":"J Eur Acad Dermatol Venereol","authors":["Messina, F","Piaserico, S"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294258","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16468","keywords":["sars-cov-2","biologic","covid-19","guselkumab","psoriasis"],"topics":["Case Report"],"weight":1,"_version_":1666138494320246785,"score":155.58011}]}